We are live on ! Find out more
VIVE

VIVEVE MED INC

Delisted

VIVE was delisted on the 18th of January, 2023.

46 hedge funds and large institutions have $91.2M invested in VIVEVE MED INC in 2017 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

417% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 6

119% more funds holding

Funds holding: 2146 (+25)

23% more capital invested

Capital invested by funds: $74.3M → $91.2M (+$16.9M)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

0.96% more ownership

Funds ownership: 64.6%65.55% (+0.96%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
46
Holders Change
+25
Holders Change %
+119.05%
% of All Funds
1.14%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
31
Increased
7
Reduced
6
Closed
6
Calls
Puts
Net Calls
Net Calls Change

VIVE Hedge Fund Activity: Q2 2017 in Review

46 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in VIVEVE MED INC (VIVE) for Q2 2017, worth a combined $91.2M — up 23% from $74.3M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new VIVE positions and 6 closed out — a net gain of 25 holders — while 7 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $4.99M. The largest seller was Wexford Capital, cutting an estimated $3.73M.

  • 46 institutional investors held VIVEVE MED INC (VIVE) as of Q2 2017, up from 21 in Q1 2017.
  • Funds reported $91.2M of VIVEVE MED INC stock for Q2 2017, up 23% quarter-over-quarter.
  • 31 funds opened new VIVEVE MED INC positions in Q2 2017 and 6 closed out, a net change of +25 holders.
  • The largest VIVEVE MED INC buyer in Q2 2017 was BlackRock, an estimated $4.99M added.
  • The largest VIVEVE MED INC seller in Q2 2017 was Wexford Capital, an estimated $3.73M sold.

Based on aggregated 13F filings for Q2 2017.